Jinglong Chen

459 total citations
19 papers, 344 citations indexed

About

Jinglong Chen is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Jinglong Chen has authored 19 papers receiving a total of 344 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hepatology, 7 papers in Epidemiology and 6 papers in Surgery. Recurrent topics in Jinglong Chen's work include Hepatocellular Carcinoma Treatment and Prognosis (14 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (6 papers) and Cancer Mechanisms and Therapy (5 papers). Jinglong Chen is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (14 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (6 papers) and Cancer Mechanisms and Therapy (5 papers). Jinglong Chen collaborates with scholars based in China, Germany and United States. Jinglong Chen's co-authors include Wendong Li, Yanjun Shen, Xiaoyan Ding, Wei Sun, Ying Teng, Huige Wang, Wei Li, Xiaodi Guo, Xiaomin Liu and Linlin Zheng and has published in prestigious journals such as Cancer, Frontiers in Immunology and World Journal of Gastroenterology.

In The Last Decade

Jinglong Chen

18 papers receiving 340 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jinglong Chen China 10 203 116 87 69 58 19 344
Xubiao Wei China 12 227 1.1× 107 0.9× 77 0.9× 46 0.7× 99 1.7× 27 407
Sawako Uchida‐Kobayashi Japan 11 293 1.4× 262 2.3× 99 1.1× 35 0.5× 54 0.9× 59 474
Shinichiro Henmi Japan 11 238 1.2× 204 1.8× 44 0.5× 29 0.4× 94 1.6× 14 346
Hirofumi Kanemura Japan 14 207 1.0× 120 1.0× 127 1.5× 26 0.4× 234 4.0× 24 533
Marc Puigvehí Spain 11 358 1.8× 266 2.3× 120 1.4× 75 1.1× 94 1.6× 24 515
Mingjie Yao China 14 151 0.7× 182 1.6× 61 0.7× 16 0.2× 73 1.3× 31 407
Eisuke Nagata Japan 10 143 0.7× 195 1.7× 49 0.6× 32 0.5× 58 1.0× 19 334
Yugo Kai Japan 11 81 0.4× 112 1.0× 126 1.4× 17 0.2× 54 0.9× 47 297
Ekapot Bhunchet Japan 9 241 1.2× 195 1.7× 32 0.4× 19 0.3× 116 2.0× 14 394
Ceen‐Ming Tang United Kingdom 6 88 0.4× 150 1.3× 91 1.0× 40 0.6× 74 1.3× 8 419

Countries citing papers authored by Jinglong Chen

Since Specialization
Citations

This map shows the geographic impact of Jinglong Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jinglong Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jinglong Chen more than expected).

Fields of papers citing papers by Jinglong Chen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jinglong Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jinglong Chen. The network helps show where Jinglong Chen may publish in the future.

Co-authorship network of co-authors of Jinglong Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Jinglong Chen. A scholar is included among the top collaborators of Jinglong Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jinglong Chen. Jinglong Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Deng, Na, et al.. (2025). CRAFITY score and nomogram predict the clinical efficacy of lenvatinib combined with immune checkpoint inhibitors in hepatocellular carcinoma. World Journal of Gastroenterology. 31(7). 101672–101672. 1 indexed citations
2.
Liu, Xiaomin, et al.. (2024). The clinical significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib and PD-1 inhibitors. Frontiers in Immunology. 15. 1380477–1380477. 3 indexed citations
3.
Ding, Xiaoyan, et al.. (2024). Transcatheter arterial chemoembolization combined with PD-1 inhibitors and Lenvatinib for hepatocellular carcinoma with portal vein tumor thrombus. World Journal of Gastroenterology. 30(8). 843–854. 7 indexed citations
4.
Sun, Shasha, Wendong Li, & Jinglong Chen. (2022). Transarterial chemoembolization combined with radiofrequency ablation in the treatment of large hepatocellular carcinoma with stage C. World Journal of Clinical Cases. 10(33). 12156–12163. 1 indexed citations
5.
Ding, Xiaoyan, et al.. (2022). Treatment options for unresectable hepatocellular carcinoma with hepatitis virus infection following sorafenib failure. Cancer Immunology Immunotherapy. 72(6). 1395–1403. 4 indexed citations
6.
Sun, Wei, et al.. (2022). Prognostic model of immune checkpoint inhibitors combined with anti-angiogenic agents in unresectable hepatocellular carcinoma. Frontiers in Immunology. 13. 1060051–1060051. 5 indexed citations
7.
Ding, Xiaoyan, Guangxin Li, Wei Sun, et al.. (2022). Sintilimab Combined with Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma in Second-Line Setting—A Multi-Center Observational Study. Frontiers in Oncology. 12. 907055–907055. 11 indexed citations
8.
Li, Wendong, Xiaoyan Ding, Wei Sun, et al.. (2022). CT-guided percutaneous chemical ablation combined with radiofrequency ablation for hepatocellular carcinomas in high-risk locations: lobaplatin vs. ethanol.. PubMed. 14(9). 6726–6736.
9.
Teng, Ying, Xiaoyan Ding, Wendong Li, Wei Sun, & Jinglong Chen. (2022). A Retrospective Study on Therapeutic Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors Plus Lenvatinib in Patients With Unresectable Hepatocellular Carcinoma. Technology in Cancer Research & Treatment. 21. 2213817062–2213817062. 28 indexed citations
10.
11.
Wang, Yongjie, et al.. (2021). Comparison of Growth Performance and Meat Quality Traits of Commercial Cross-Bred Pigs versus the Large Black Pig Breed. Animals. 11(1). 200–200. 29 indexed citations
12.
13.
Shen, Yanjun, Huige Wang, Wendong Li, & Jinglong Chen. (2019). Prognostic significance of the CRP/Alb and neutrophil to lymphocyte ratios in hepatocellular carcinoma patients undergoing TACE and RFA. Journal of Clinical Laboratory Analysis. 33(9). e22999–e22999. 28 indexed citations
14.
Shen, Yanjun, Huige Wang, Xiangmei Chen, Wendong Li, & Jinglong Chen. (2019). <p>Prognostic significance of lymphocyte-to-monocyte ratio and platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization and radiofrequency ablation</p>. OncoTargets and Therapy. Volume 12. 7129–7137. 23 indexed citations
15.
Sun, Shasha, Xiangyi Wang, & Jinglong Chen. (2019). Using Pre-Treatment Neutrophil-to-Lymphocyte Ratio to Predict the Prognosis of Young Patients with Hepatocellular Carcinoma Implemented Minimally Invasive Treatment. Journal of Adolescent and Young Adult Oncology. 9(1). 85–89. 9 indexed citations
16.
Sun, Wei, Xiaoyan Ding, Jinglong Chen, et al.. (2017). [The combination of percutaneous iohexol-ethanol injection with radiofrequency ablation for the treatment of primary liver cancer in high-risk locations].. PubMed. 39(9). 695–700. 1 indexed citations
17.
Li, Li, et al.. (2017). Clinical characteristics of hepatocellular carcinoma patients with normal serum alpha‐fetoprotein level: A study of 112 consecutive cases. Asia-Pacific Journal of Clinical Oncology. 14(5). e336–e340. 4 indexed citations
18.
Huang, Yanping, Shixing Gao, Jinglong Chen, et al.. (2016). Maternal butyrate supplementation induces insulin resistance associated with enhanced intramuscular fat deposition in the offspring. Oncotarget. 8(8). 13073–13084. 46 indexed citations
19.
Qiao, Yong, Jinglong Chen, Xin Li, et al.. (2014). Serum gp73 is also a biomarker for diagnosing cirrhosis in population with chronic HBV infection. Clinical Biochemistry. 47(16-17). 216–222. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xubiao Wei Breakdown of academic impact, for papers by Sawako Uchida‐Kobayashi Breakdown of academic impact, for papers by Shinichiro Henmi Breakdown of academic impact, for papers by Hirofumi Kanemura Breakdown of academic impact, for papers by Marc Puigvehí Breakdown of academic impact, for papers by Mingjie Yao Breakdown of academic impact, for papers by Eisuke Nagata Breakdown of academic impact, for papers by Yugo Kai Breakdown of academic impact, for papers by Ekapot Bhunchet Breakdown of academic impact, for papers by Ceen‐Ming Tang
Rankless by CCL
2026